JP2017528461A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528461A5
JP2017528461A5 JP2017512983A JP2017512983A JP2017528461A5 JP 2017528461 A5 JP2017528461 A5 JP 2017528461A5 JP 2017512983 A JP2017512983 A JP 2017512983A JP 2017512983 A JP2017512983 A JP 2017512983A JP 2017528461 A5 JP2017528461 A5 JP 2017528461A5
Authority
JP
Japan
Prior art keywords
cancer
tumor
cell
alkyl
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017512983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528461A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/049225 external-priority patent/WO2016040508A1/en
Publication of JP2017528461A publication Critical patent/JP2017528461A/ja
Publication of JP2017528461A5 publication Critical patent/JP2017528461A5/ja
Pending legal-status Critical Current

Links

JP2017512983A 2014-09-10 2015-09-09 置換ピロリジンカルボキサミド化合物 Pending JP2017528461A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462048763P 2014-09-10 2014-09-10
US62/048,763 2014-09-10
US201562146804P 2015-04-13 2015-04-13
US62/146,804 2015-04-13
PCT/US2015/049225 WO2016040508A1 (en) 2014-09-10 2015-09-09 Substituted pyrrolidine carboxamide compounds

Publications (2)

Publication Number Publication Date
JP2017528461A JP2017528461A (ja) 2017-09-28
JP2017528461A5 true JP2017528461A5 (enExample) 2018-10-18

Family

ID=55459531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512983A Pending JP2017528461A (ja) 2014-09-10 2015-09-09 置換ピロリジンカルボキサミド化合物

Country Status (6)

Country Link
US (2) US20170247326A1 (enExample)
EP (1) EP3193609A4 (enExample)
JP (1) JP2017528461A (enExample)
AU (1) AU2015315177A1 (enExample)
CA (1) CA2960277A1 (enExample)
WO (1) WO2016040508A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017004589A2 (pt) 2014-09-10 2018-01-23 Epizyme Inc composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
AU2015315174B2 (en) 2014-09-10 2019-12-12 Epizyme, Inc. Smyd inhibitors
WO2016040511A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
EP3190891B1 (en) 2014-09-10 2020-01-15 Epizyme, Inc. Isoxazolecarboxamide substituted by a cyclohexylamine as smyd protein inhibitors
CA2960274A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamide compounds
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROBENZIMIDAZOLONES
ES2995214T3 (en) 2019-03-06 2025-02-07 C4 Therapeutics Inc Heterocyclic compounds for medical treatment
GB201912674D0 (en) * 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1428493A (en) * 1973-05-02 1976-03-17 Science Union & Cie Heterocyclic amides processes for their preparation and pharma ceutical compositions containing them
JPS52128368A (en) * 1976-04-15 1977-10-27 Yamanouchi Pharmaceut Co Ltd Novel carboxylic acid amide derivatives and their preparation
GR66581B (enExample) * 1978-02-21 1981-03-27 Delalande Sa
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
DE10148290A1 (de) * 2001-09-29 2003-04-17 Bayer Cropscience Gmbh Heterocyclische Amide, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung
AU2002363250A1 (en) * 2001-11-01 2003-05-12 Icagen, Inc. Pyrazole-amides and-sulfonamides
DE602004015429D1 (de) * 2003-03-11 2008-09-11 Pfizer Prod Inc Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf)
EP1603917B1 (en) * 2003-03-14 2010-11-24 MediGene Ltd. Immunomodulating heterocyclic compounds
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
US7514448B2 (en) * 2004-04-02 2009-04-07 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
WO2006086609A2 (en) * 2005-02-10 2006-08-17 Axys Pharmaceuticals, Inc. Inhibitors of tryptase
WO2006107923A1 (en) * 2005-04-05 2006-10-12 Boehringer Ingelheim International Gmbh Substituted benzylimidazoles useful for the treatment of inflammatory diseases
CN101160301B (zh) * 2005-04-12 2012-03-28 索尔瓦药物有限公司 氨基烷基-酰胺基甲基-取代的2-(4-磺酰基氨基)-3-羟基-3,4-二氢-2h-色烯-6-基衍生物以及它们作为钾通道阻断剂的用途
WO2007011760A2 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
EA017376B1 (ru) * 2006-10-24 2012-12-28 Янссен Фармацевтика Нв Производные тетрагидронафталин-1-карбоновой кислоты, ингибирующие мтр
EP1975165A1 (de) * 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
AR066721A1 (es) * 2007-05-24 2009-09-09 Wyeth Corp Derivados de benzo[d]imidazol-1-il, composicion farmaceutica, proceso de preparacion y uso.
AU2008279759A1 (en) * 2007-07-20 2009-01-29 Merck & Co., Inc. Pyrazolo[1,5-a]pyrimidine derivatives
EP2307378A1 (en) * 2008-06-18 2011-04-13 Pfizer Limited Nicotinamide derivatives
WO2010017046A1 (en) * 2008-08-05 2010-02-11 Merck & Co., Inc. Pyrazolo[1,5-a]pyridines as mark inhibitors
JP2013028538A (ja) * 2009-11-13 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 新規アミド誘導体
AU2013352304C1 (en) * 2012-11-29 2018-03-22 Chemocentryx, Inc. CXCR7 antagonists

Similar Documents

Publication Publication Date Title
JP2017538659A5 (enExample)
JP2017511801A5 (enExample)
AU2017221802B2 (en) Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
CA2807620C (en) Pharmaceutically active compounds as axl inhibitors
JP2017528464A5 (enExample)
US9546156B2 (en) N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
US9790210B2 (en) N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
CN111170999B (zh) Egfr抑制剂及其制备和应用
US9981959B2 (en) Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
JP5256047B2 (ja) ピロロ[3,2−c]ピリジン−4−オン2−インドリノン(indolinone)プロテインキナーゼ阻害剤
CN112601747B (zh) 作为malt1抑制剂的吡唑衍生物
JP2017528460A5 (enExample)
KR20100110344A (ko) C―met의 저해제로서 활성을 나타내는 융합 피리딘
CZ20001709A3 (cs) Deriváty thienopyrimidu a thienopyridinu, farmaceutické kompozice a způsoby léčení na jejich bázi
JP2017538659A (ja) Smyd阻害剤
EP3033342A1 (en) Annelated pyrroles and their use as crac inhibitors
US20160272592A1 (en) N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
NZ612909A (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
JP2017528461A (ja) 置換ピロリジンカルボキサミド化合物
JP2017527577A (ja) 置換ピロリジン化合物
JP2017526706A5 (enExample)
JP2017527576A5 (enExample)
US20230095520A1 (en) Pharmaceutical composition for preventing or treating cancer comprising azole derivatives or pharmaceutically acceptable salt thereof
KR20150047609A (ko) 피리딘 유도체 및 의약
JP7768592B2 (ja) 医薬化合物